# Study Design Checklists

## CONSORT 2010 Checklist (Randomized Controlled Trials)

| Section | Item | Description |
|---------|------|-------------|
| **Title and Abstract** |
| | 1a | Identification as a randomized trial in the title |
| | 1b | Structured summary of trial design, methods, results, and conclusions |
| **Introduction** |
| Background | 2a | Scientific background and explanation of rationale |
| Objectives | 2b | Specific objectives or hypotheses |
| **Methods** |
| Trial design | 3a | Description of trial design (parallel, factorial) |
| | 3b | Important changes to methods after trial commencement |
| Participants | 4a | Eligibility criteria for participants |
| | 4b | Settings and locations where data were collected |
| Interventions | 5 | Interventions for each group with sufficient detail |
| Outcomes | 6a | Completely defined pre-specified primary and secondary outcomes |
| | 6b | Any changes to trial outcomes after trial commencement |
| Sample size | 7a | How sample size was determined |
| | 7b | When applicable, explanation of any interim analyses |
| Randomization | | |
| - Sequence generation | 8a | Method used to generate random allocation sequence |
| | 8b | Type of randomization; details of any restriction |
| - Allocation concealment | 9 | Method used to implement random allocation sequence |
| - Implementation | 10 | Who generated sequence, enrolled, assigned participants |
| Blinding | 11a | If done, who was blinded after assignment |
| | 11b | Description of the similarity of interventions |
| Statistical methods | 12a | Statistical methods for comparing groups for primary outcome |
| | 12b | Methods for additional analyses (subgroup, adjusted) |
| **Results** |
| Participant flow | 13a | For each group, numbers assigned, received treatment, analyzed |
| | 13b | For each group, losses and exclusions with reasons |
| Recruitment | 14a | Dates defining recruitment and follow-up periods |
| | 14b | Why trial ended or was stopped |
| Baseline data | 15 | Table showing baseline demographic and clinical characteristics |
| Numbers analyzed | 16 | For each group, number analyzed in each analysis |
| Outcomes and estimation | 17a | For each primary and secondary outcome, results for each group |
| | 17b | For binary outcomes, presentation of both absolute and relative effect sizes |
| Ancillary analyses | 18 | Results of any other analyses performed |
| Harms | 19 | All important harms or unintended effects in each group |
| **Discussion** |
| Limitations | 20 | Trial limitations, addressing sources of potential bias |
| Generalizability | 21 | Generalizability (external validity) of trial findings |
| Interpretation | 22 | Interpretation consistent with results, balancing benefits and harms |
| **Other Information** |
| Registration | 23 | Registration number and name of trial registry |
| Protocol | 24 | Where full trial protocol can be accessed |
| Funding | 25 | Sources of funding and other support |

---

## STROBE Checklist (Observational Studies)

### Common Items for All Observational Studies

| Section | Item | Description |
|---------|------|-------------|
| **Title and Abstract** |
| | 1 | Indicate the study's design in title or abstract |
| **Introduction** |
| Background | 2 | Explain the scientific background and rationale |
| Objectives | 3 | State specific objectives, including any pre-specified hypotheses |
| **Methods** |
| Study design | 4 | Present key elements of study design early in the paper |
| Setting | 5 | Describe the setting, locations, and relevant dates |
| Participants | | |
| - Cohort | 6a | Give the eligibility criteria, and sources and methods of selection |
| | 6b | For matched studies, give matching criteria and number of exposed/unexposed |
| - Case-Control | 6a | Give the eligibility criteria, and sources and methods of case and control selection |
| | 6b | Give the matching criteria and the number of controls per case |
| - Cross-sectional | 6a | Give the eligibility criteria, and sources and methods of selection |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, confounders, effect modifiers |
| Data sources | 8 | For each variable of interest, give sources of data and details of assessment methods |
| Bias | 9 | Describe any efforts to address potential sources of bias |
| Study size | 10 | Explain how the study size was arrived at |
| Quantitative variables | 11 | Explain how quantitative variables were handled |
| Statistical methods | 12a | Describe all statistical methods for each objective |
| | 12b | Describe methods for addressing confounding |
| | 12c | Describe methods for subgroups/interactions |
| | 12d | Explain how missing data were addressed |
| | 12e | For cohort: describe methods for loss to follow-up |
| | 12f | For case-control: describe matching methods |
| | 12g | For cross-sectional: describe sampling methods |
| **Results** |
| Participants | 13a | Report numbers of individuals at each stage of study |
| | 13b | Give reasons for non-participation at each stage |
| | 13c | Consider use of a flow diagram |
| Descriptive data | 14a | Give characteristics of study participants |
| | 14b | Indicate number of participants with missing data for each variable |
| | 14c | For cohort: summarize follow-up time |
| Outcome data | 15 | Report numbers in each exposure category or summary measures |
| Main results | 16a | Give unadjusted estimates and confounder-adjusted estimates |
| | 16b | Report category boundaries when continuous variables were categorized |
| | 16c | If relevant, consider translating estimates of relative risk into absolute risk |
| Other analyses | 17 | Report other analyses doneâ€”subgroups, interactions, sensitivity analyses |
| **Discussion** |
| Key results | 18 | Summarize key results with reference to study objectives |
| Limitations | 19 | Discuss limitations of the study, considering bias or imprecision |
| Interpretation | 20 | Give a cautious overall interpretation of results |
| Generalizability | 21 | Discuss the generalizability (external validity) of the results |
| **Other Information** |
| Funding | 22 | Give the source of funding and the role of the funders |

### Cohort-Specific Items

| Item | Description |
|------|-------------|
| 8 | For each outcome, describe the method of outcome ascertainment |
| 15 | Report follow-up time, incidence rates, and measures of association |
| 16a | Report hazard ratios, rate ratios, or risk ratios with confidence intervals |

### Case-Control-Specific Items

| Item | Description |
|------|-------------|
| 6a | Give rationale for the choice of cases and controls |
| 8 | If applicable, describe methods for matching cases and controls |
| 15 | Report numbers in each exposure category for cases and controls |
| 16a | Report odds ratios with confidence intervals |

### Cross-Sectional-Specific Items

| Item | Description |
|------|-------------|
| 6a | Give rationale for the choice of the study population |
| 15 | Report numbers in each exposure category or prevalence estimates |
| 16a | Report prevalence ratios or odds ratios with confidence intervals |

---

## PRISMA 2020 Checklist (Systematic Reviews)

| Section | Item | Description |
|---------|------|-------------|
| **Title** |
| | 1 | Identify the report as a systematic review |
| **Abstract** |
| | 2 | Structured summary including objectives, data sources, eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications |
| **Introduction** |
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge |
| Objectives | 4 | Provide an explicit statement of the questions being addressed |
| **Methods** |
| Protocol | 5 | Indicate if a review protocol exists and where it can be accessed |
| Eligibility | 6 | Specify study characteristics and report characteristics used as criteria |
| Information sources | 7 | Describe all information sources in the search and date last searched |
| Search | 8 | Present full electronic search strategy for at least one database |
| Study selection | 9 | State the process for selecting studies |
| Data collection | 10 | Describe method of data extraction from reports |
| Data items | 11 | List and define all variables for which data were sought |
| Risk of bias | 12 | Describe methods used for assessing risk of bias |
| Summary measures | 13 | State the principal summary measures |
| Synthesis | 14 | Describe the methods of handling data and combining results |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect cumulative evidence |
| Additional analyses | 16 | Describe methods of additional analyses |
| **Results** |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted |
| Risk of bias within studies | 19 | Present data on risk of bias of each study |
| Results of individual studies | 20 | For all outcomes, present simple summary data for each study |
| Synthesis of results | 21 | Present results of each meta-analysis done |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies |
| Additional analysis | 23 | Give results of additional analyses |
| **Discussion** |
| Summary of evidence | 24 | Summarize the main findings with the strength of evidence |
| Limitations | 25 | Discuss limitations at study and outcome level |
| Conclusions | 26 | Provide a general interpretation of the results |
| **Funding** |
| | 27 | Describe sources of funding for the systematic review |

---

## STREGA Checklist (Genetic Association Studies)

Extension of STROBE for genetic epidemiology:

| Item | Description |
|------|-------------|
| 7 | Describe genetic exposures (genes, variants, haplotypes) |
| 8 | Describe laboratory methods, genotyping platform, quality control |
| 11 | Describe Hardy-Weinberg equilibrium testing |
| 12 | Describe methods for population stratification |
| 16 | Describe haplotype analysis methods |
| 20 | Report allele frequencies, Hardy-Weinberg equilibrium p-values |

---

## RECORD Checklist ( Routinely Collected Data)

Extension of STROBE for studies using routinely collected health data:

| Item | Description |
|------|-------------|
| 6.1 | Describe the methods of cleaning and validating the data |
| 12.2 | Describe methods used to address missing data |
| 12.3 | Describe methods used for validation of codes/outcomes |
| 14.1 | Describe the data source and linkage methods |
| 19.1 | Describe the validation of codes/outcomes |

---

## Quick Reference: Which Checklist to Use

| Study Type | Checklist |
|------------|-----------|
| Randomized Controlled Trial | CONSORT |
| Non-randomized intervention | TREND |
| Cohort study | STROBE (+ RECORD if routinely collected data) |
| Case-control study | STROBE |
| Cross-sectional study | STROBE |
| Systematic review | PRISMA |
| Meta-analysis | PRISMA |
| Diagnostic accuracy study | STARD |
| Genetic association study | STREGA |
| Prediction model development | TRIPOD |
| Clinical practice guideline | AGREE |
| Quality improvement study | SQUIRE |
| Economic evaluation | CHEERS |
| Case report | CARE |

---

## Resources

- **CONSORT**: https://www.consort-statement.org/
- **STROBE**: https://www.strobe-statement.org/
- **PRISMA**: http://www.prisma-statement.org/
- **EQUATOR Network**: https://www.equator-network.org/
